RNA interference: A potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer

Cancer Biology and Therapy

Volumn 3, Issue 12, 2004, Pages 1283-1289

  Zhang, Lin ^a,b   Yang, Nuo ^c   Liang, Shun ^b   Barchetti, Andrea ^b   Vezzani, Cristina ^b   Huang, Jia ^a   O'Brien Jenkins, Ann ^b   Rubin, Stephen C ^c   Coukos, George ^a,b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Ovarian cancer; PI3 kinase; PIK3CA; RNA interference

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; SMALL INTERFERING RNA; ISOPROTEIN; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL CELL; ARTICLE; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; KNOCKOUT GENE; MOUSE; NONHUMAN; OVARY CANCER; PROTEIN TARGETING; RNA INTERFERENCE; RNA SEQUENCE; ANIMAL; CELL CULTURE; CELL PROLIFERATION; DRUG ANTAGONISM; GENE VECTOR; GENETICS; METABOLISM; OVARY TUMOR; WESTERN BLOTTING;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BLOTTING, WESTERN; CELL PROLIFERATION; FEMALE; GENETIC VECTORS; HUMANS; MICE; OVARIAN NEOPLASMS; PROTEIN ISOFORMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 22344446375     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.12.1388     Document Type: Article

References (41)

1. Stein RC, Waterfield MD. PI3-kinase inhibition: A target for drug development? Mol Med Today 2000; 6:347-57.
2. Katso R, Okkenhaug K, Ahmadi K, White S, Timms J, Waterfield MD. Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 2001; 17:615-75.
3. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
4. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296:1655-7.
5. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, Pinkel D, Powell B, Mills GB, Gray JW. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21:99-102.
6. Zhang L, Yang N, Katsaros D, Huang W, Park JW, Fracchioli S, Vezzani C, Rigault de la Longrais LA, Yao W, Rubin SC, Coukos G. The oncogene phosphatidylinositol 3′-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Res 2003; 63:4225-31.
7. Campbell IG, Russell SE, Choong DYH, Montgomery KG, Ciavarella ML, Hooi CSF, Cristiano BE, Pearson RB, Phillips WE. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Research 2004; 64:7678-81.
8. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 2004; In press.
9. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, Fults DW, Velculescu VE, Bigner DD, Yan H. Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 2004; 64:5048-50.
10. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002; 26:199-213.
11. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. Nat Rev Genet 2002; 3:737-47.
12. Hannon GJ. RNA interference. Nature 2002; 418:244-51.
13. Shi Y. Mammalian RNAi for the masses. Trends Genet 2003; 19:9-12.
14. Novina CD, Murray MF, Dykxhoorn DM, Beresford PJ, Riess J, Lee SK, Collman RG, Lieberman J, Shankar P, Sharp PA. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002; 8:081-6.
15. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2:243-7.
16. Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 2002; 99:6047-52.
17. Sui G, Soohoo C, Affar el B, Gay F, Shi Y, Forrester WC. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA 2002; 99:5515-20.
18. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296:550-3.
19. Paddison PJ, Gaudy AA, Bernstein E, Hannon GJ, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002; 16:948-58.
20. Paul CP, Good PD, Winer I, Engelke DR. Effective expression of small interfering RNA in human cells. Nat Biotechnol 2002; 20:505-8.
21. Miyagishi M, Taira K. U6 promoter driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat Biotechnol 2002; 20:497-500.
22. Lee NS, Dohjima T, Bauer G, Li H, Li MJ, Ehsani A, Salvaterra P, Rossi J. Expression of small interfering RNAs targeted against HlV-1 rev transcripts in human cells. Nat Biotechnol 2002; 20:500-5.
23. Zeng Y, Wagner EJ, Cullen BR. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol Cell 2002; 9:1327-33.
24. McManus MT, Petersen CP, Haines BB, Chen J, Sharp PA. Gene silencing using micro-RNA designed hairpins. Rna 2002; 8:842-50.
25. Czauderna F, Santel A, Hinz M, Fechtner M, Durieux B, Fisch G, Leenders F, Arnold W, Giese K, Klippel A, Kaufmann J. Inducible shRNA expression for application in a prostate cancer mouse model. Nucleic Acids Res 2003; 31:e127.
26. Czauderna F, Fechtner M, Aygun H, Arnold W, Klippel A, Giese K, Kaufmann J. Functional studies of the PI3-kinase signalling pathway employing synthetic and expressed siRNA. Nucleic Acids Res 2003; 31:670-82.
27. Zhang L, Conejo-Garcia JR, Yang N, Huang W, Mohamed-Hadley A, Yao W, Benencia F, Coukos G. Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in marine ovarian cancer cells. Biochem Biophys Res Commun 2002; 292:860-8.
28. Zhang L, Yang N, Conejo-Garcia JR, Katsaros D, Mohamed-Hadley A, Fracchioli S, Schlienger K, Toll A, Levine B, Rubin SC, Coukos G. Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clin Cancer Res 2003; 9:264-72.
29. Zhang L, Yang N, Garcia JR, Mohamed A, Benencia F, Rubin SC, Allman D, Coukos G. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 2002; 161:2295-309.
30. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411:494-8.
31. Tuschl T. Expanding small RNA interference. Nat Biotechnol 2002; 20:446-8.
32. Ilves H, Barske C, Junker U, Bohnlein E, Veres G. Retroviral vectors designed for targeted expression of RNA polymerase III-driven transcripts: A comparative study. Gene 1996; 171:203-8.
33. Hasuwa H, Kaseda K, Einarsdottir T, Okabe M. Small interfering RNA and gene silencing in transgenic mice and rats. FEBS Lett 2002; 532:227-30.
34. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 2003; 100:183-8.
35. Tiscornia G, Singer O, Ikawa M, Verma IM. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci USA 2003; 100:1844-8.
36. Hamada M, Ohtsuka T, Kawaida R, Koizumi M, Morita K, Furukawa H, Imanishi T, Miyagishi M, Taira K. Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3′-ends of siRNAs. Antisense Nucleic Acid Drug Dev 2002; 12:301-9.
37. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20:1006-10.
38. Gou D, Narasaraju T, Chintagari NR, Jin N, Wang P, Liu L. Gene silencing in alveolar type II cells using cell-specific promoter in vitro and in vivo. Nucleic Acids Res 2004; 32:e134.
39. Godwin AK, Miller PD, Getts LA, Jackson K, Sonoda G, Schray KJ, Testa JR, Hamilton TC. Retroviral-like sequences specifically expressed in the rat ovary detect genetic differences between normal and transformed rat ovarian surface epithelial cells. Endocrinology 1995; 136:4640-9.
40. Bao R, Connolly DC, Murphy M, Green J, Weinstein JK, Pisarcik DA, Hamilton TC. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 2002; 94:522-8.
41. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003; 63:1389-97.